Dimezeft TZ 1.125 is a potent combination of Ceftazidime (a third-generation cephalosporin antibiotic) and Tazobactam (a beta-lactamase inhibitor) used for the treatment of a broad range of severe bacterial infections. This combination enhances the efficacy of ceftazidime against beta-lactamase-producing bacteria that would otherwise be resistant.
Ceftazidime acts by inhibiting bacterial cell wall synthesis, leading to the death of susceptible bacteria. Tazobactam, on the other hand, protects ceftazidime from degradation by beta-lactamase enzymes secreted by resistant bacteria, thereby broadening the antimicrobial spectrum of the formulation.
Dimezeft TZ 1.125 is indicated in the treatment of serious infections such as:
-
Lower respiratory tract infections (e.g., pneumonia, bronchitis)
-
Urinary tract infections
-
Intra-abdominal infections
-
Skin and soft tissue infections
-
Bone and joint infections
-
Septicemia and bacteremia
-
Infections in neutropenic patients
This injection is typically administered in a hospital setting under the supervision of healthcare professionals. It is suitable for both adult and pediatric patients, depending on clinical evaluation.
Its powerful activity against both gram-negative and some gram-positive organisms makes it a preferred choice in empirical therapy for critically ill patients until culture and sensitivity reports are available.
The formulation is well-tolerated in most patients; however, dosage adjustments may be necessary in cases of renal impairment. It is essential to complete the full course as prescribed to prevent the development of antibiotic resistance.